PFE and BMY Related Headlines

Go Back

Jul 17, 2014 08:07AM Bristol-Myers Squibb (BMY), Pfizer (PFE) Entroll First Patient into Eliquis Phase IV
Jun 27, 2014 07:04AM Bristol-Myers Squibb's (BMY) Daklinza Receives Positive CHMP Opinion
May 14, 2014 03:13PM Drugs Stocks on Watch Ahead of ASCO Abstracts Release
Mar 14, 2014 01:04PM Bristol-Myers (BMY), Pfizer (PFE) Report FDA Approval of Eliquis sNDA
Jan 13, 2014 08:17AM Portola Pharmaceuticals (PTLA) Enters Second Collaboration Deal with Bristol-Myers (BMY)
Dec 19, 2013 05:02PM Bristol-Myers (BMY), Pfizer (PFE) sNDA for ELIQUIS Approved by FDA
Aug 30, 2013 02:29PM Drug Companies on Watch Heading Into ESC Meeting; Goldman Comments (JNJ) (BMY) (PFE)

PFE and BMY Related Press Releases

Go Back

Aug 20, 2014 08:00AM Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014
Jul 29, 2014 07:00AM European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Jul 17, 2014 08:06AM Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion
Jun 27, 2014 07:00AM Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Jan 13, 2014 08:00AM Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With

PFE and BMY Related SEC Filings

Go Back